A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
A Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab as First Line Therapy for Locally Advanced or Metastatic Non-squamous and Squamous Non-small Cell Lung Cancer Subjects (CANOPY-1)
This was a Phase III study of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab in previously untreated locally advanced or metastatic non-squamous and squamous NSCLC participants.
The study primarily assessed the safety and tolerability (safety run-in Part A) of pembrolizumab plus platinum-based doublet chemotherapy with canakinumab, and then, the efficacy (double-blind, randomized, placebo-controlled Part B) of pembrolizumab plus platinum-based doublet chemotherapy with or without canakinumab.
Key inclusion criteria:
Key exclusion criteria:
Caba, Buenos Aires C1426ANZ, Argentina
Caba, C1431FWO, Argentina
Wooloongabba, Queensland 4102, Australia
Hyderabad, Andhra Pradesh 500034, India
Sunto Gun, Shizuoka 4118777, Japan
Chuo Ku, Tokyo 1040045, Japan
Tomaszw Mazowiecki, 97-200, Poland
Kosice-Saca, 958 01, Slovakia
Las Palmas de Gran C, Las Palmas 35016, Spain